We are live on
!
Find out more
Two Sigma Advisers Portfolio holdings
AUM
$51.4B
1-Year Est. Return
31.07%
This Fund
S&P 500
This Quarter
Est. Return
-16.56%
1 Year Est. Return
+31.07%
3 Year Est. Return
+128.94%
5 Year Est. Return
+161.75%
10 Year Est. Return
+607.04%
AUM
$35.3B
AUM Growth
-$2.37B
(-6.3%)
Cap. Flow
+$5.08B
Cap. Flow
% of AUM
14.42%
Top 10 Holdings %
Top 10 Hldgs %
12.79%
Holding
3,021
New
306
Increased
1,176
Reduced
1,104
Closed
398
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Netflix
NFLX
|
+$410M |
| 2 |
Snap
SNAP
|
+$321M |
| 3 |
Altria Group
MO
|
+$312M |
| 4 |
Meta Platforms (Facebook)
META
|
+$295M |
| 5 |
Intel
INTC
|
+$283M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CERN
Cerner Corp
CERN
|
+$407M |
| 2 |
AbbVie
ABBV
|
+$283M |
| 3 |
S&P Global
SPGI
|
+$251M |
| 4 |
Amazon
AMZN
|
+$221M |
| 5 |
Eli Lilly
LLY
|
+$197M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.06% |
| 2 | Healthcare | 18.6% |
| 3 | Financials | 10.47% |
| 4 | Industrials | 10.2% |
| 5 | Consumer Discretionary | 7.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2301
Voyager Therapeutics
VYGR
$187M
| $181K | ﹤0.01% |
30,700
+17,200
| +127% | +$116K |
|
2302
XBiotech
XBIT
$68.9M
| $179K | ﹤0.01% |
+31,800
| New | +$214K |
|
|
SIEN
2303
DELISTED
Sientra, Inc.
SIEN
| $178K | ﹤0.01% |
21,230
+1,920
| +10% | +$26.2K |
|
|
SYBX
2304
DELISTED
Synlogic
SYBX
| $177K | ﹤0.01% |
10,253
-827
| -7% | -$17.9K |
|
2305
Interface
TILE
$1.96B
| $177K | ﹤0.01% |
14,100
-13,400
| -49% | -$178K |
|
2306
Arbutus Biopharma
ABUS
$871M
| $175K | ﹤0.01% |
64,400
-171,800
| -73% | -$440K |
|
2307
Millicom
TIGO
$16B
| $172K | ﹤0.01% |
+12,000
| New | +$246K |
|
|
LRFC
2308
DELISTED
Logan Ridge Finance Corp
LRFC
| $169K | ﹤0.01% |
10,721
-7,900
| -42% | -$154K |
|
|
RDBX
2309
DELISTED
Redbox Entertainment Inc. Class A Common Stock
RDBX
| $169K | ﹤0.01% |
+22,900
| New | +$135K |
|
2310
Dyne Therapeutics
DYN
$4.24B
| $167K | ﹤0.01% |
24,300
-24,200
| -50% | -$167K |
|
|
HMTV
2311
DELISTED
Hemisphere Media Group, Inc.
HMTV
| $167K | ﹤0.01% |
+21,900
| New | +$127K |
|
|
OSG
2312
Octave Specialty Group
OSG
$258M
| $166K | ﹤0.01% |
14,600
-22,800
| -61% | -$216K |
|
2313
Shattuck Labs
STTK
$672M
| $166K | ﹤0.01% |
40,800
-44,200
| -52% | -$160K |
|
|
VNET
2314
VNET Group
VNET
$2.04B
| $164K | ﹤0.01% |
27,200
+900
| +3% | +$5.33K |
|
|
FCRD
2315
DELISTED
First Eagle Alternative Capital BDC, Inc. Common Stock
FCRD
| $162K | ﹤0.01% |
45,668
-5,400
| -11% | -$21.1K |
|
|
EPIX
2316
DELISTED
ESSA Pharma
EPIX
| $161K | ﹤0.01% |
51,100
-61,900
| -55% | -$346K |
|
2317
Riverview Bancorp
RVSB
$108M
| $161K | ﹤0.01% |
24,400
-12,800
| -34% | -$87.8K |
|
2318
Cato Corp
CATO
$64.1M
| $160K | ﹤0.01% |
13,800
-800
| -5% | -$10.5K |
|
|
GTHX
2319
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $158K | ﹤0.01% |
32,000
-50,200
| -61% | -$278K |
|
|
CTHR
2320
DELISTED
Charles & Colvard Ltd
CTHR
| $158K | ﹤0.01% |
12,970
-1,600
| -11% | -$22.5K |
|
|
BNR
2321
Burning Rock Biotech
BNR
$99.1M
| $157K | ﹤0.01% |
+5,400
| New | +$241K |
|
|
CKPT
2322
DELISTED
Checkpoint Therapeutics
CKPT
| $156K | ﹤0.01% |
15,100
-10,470
| -41% | -$137K |
|
2323
Protara Therapeutics
TARA
$227M
| $156K | ﹤0.01% |
53,118
-12,800
| -19% | -$46.8K |
|
|
STSA
2324
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $156K | ﹤0.01% |
37,600
-29,000
| -44% | -$102K |
|
2325
Atea Pharmaceuticals
AVIR
$386M
| $155K | ﹤0.01% |
21,800
-75,500
| -78% | -$515K |
|
Similar funds
CWM
VRS
FAF
BGIM
CIM
PPFA
Two Sigma Advisers's Q2 2022 Portfolio in Review
As of Q2 2022, Two Sigma Advisers held 3,021 positions worth $35.3B, down 6.3% from $37.6B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Two Sigma Advisers deployed $5.08B of net new capital in Q2 2022, opening 306 new positions and adding to 1,176 existing holdings. Its largest new stake was Snap: 14,064,077 shares worth $185M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 25% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was AbbVie, an estimated $283M trimmed.
- Two Sigma Advisers's largest Q2 2022 buy was Snap: 14,064,077 shares worth $185M.
- Two Sigma Advisers added most to Netflix in Q2 2022, an estimated $410M increase.
- Two Sigma Advisers's biggest Q2 2022 reduction was AbbVie, cutting an estimated $283M.
- Two Sigma Advisers fully exited Cerner Corp in Q2 2022, selling an estimated $407M.
- Two Sigma Advisers's ten largest holdings make up 13% of its $35.3B portfolio in Q2 2022.
- Two Sigma Advisers opened 306 new positions and closed 398 in Q2 2022.
- Two Sigma Advisers's portfolio value fell 6.3% quarter-over-quarter to $35.3B.
Based on Two Sigma Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.